Explore GLP-1 receptor agonists with experts Judith Heij-Hadavi and Nicole Snow: molecular design, patient care, oral therapies, and analytical insights.
GLP-1 Therapies in Transition: Analytical and Clinical Insights for Experts
In the second episode of our GLP-1 Therapy Insights series, experts Judith Hey-Hadavi from Worldwide Clinical Trials and Nicole Snow from Olympia Pharmaceuticals discuss the evolution of GLP-1 receptor agonists from protein-based therapies to small-molecule options.
This episode examines the pharmacologic basis of GLP-1 adverse reactions, dose titration strategies, and patient-specific factors shaping therapy safety.
Judith Hey-Hadavi and Nicole Snow discuss GLP-1 receptor agonists, emphasizing personalized dosing, side effect management, and lifestyle support to optimize weight loss and patient outcomes.
Judith Hey-Hadavi and Nicole Snow discuss staying current on GLP-1 research and managing therapy side effects to support patient outcomes.
Judith Hey-Hadavi and Nicole Snow explore GLP-1 drug shortages, the safety and regulation of compounded alternatives, and strategies for patient education and proper administration to ensure effective and safe therapy.
The speakers highlight emerging trends in GLP-1 therapy, including personalized dosing, weight maintenance, combination treatments, and global innovations shaping the future of obesity management.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
4
Testing Plastic Packaging for PFAS Without SPE: A Fast, Cost-Effective Direct Shoot LC-MS/MS Method on the QSight® 500 System That Meets Regulatory Requirements
5